Evidence map›Paper›PMID 36449018›Full record

ArticleCancer research2023

A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes.

Anna Wuestefeld, Viktoriia Iakovleva, Shirlyn Xue Ling Yap, Agnes Bee Leng Ong, Daniel Q Huang, Timothy Wai Ho Shuen, Han Chong Toh, Yock Young Dan, Lars Zender, Torsten Wuestefeld

Open access · hybridAbstract read
In one paragraph

Article in Cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Redefining senescence through hepatocyte fate changes in liver diseases.Trends in endocrinology and metabolism: TEM · 2026
    Review
  4. Trefoil Factor-3 Is a Hypoxia-Triggered Pro-Tumorigenic Factor in Hepatoblastoma.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Anna WuestefeldLaboratory of In Vivo Genetics & Gene Therapy, Genome Institute of Singapore, Singapore.ORCID 0000-0002-2430-4397
Viktoriia IakovlevaLaboratory of In Vivo Genetics & Gene Therapy, Genome Institute of Singapore, Singapore.ORCID 0000-0002-1824-2556
Shirlyn Xue Ling YapLaboratory of In Vivo Genetics & Gene Therapy, Genome Institute of Singapore, Singapore.ORCID 0000-0002-3944-0631
Agnes Bee Leng OngLaboratory of In Vivo Genetics & Gene Therapy, Genome Institute of Singapore, Singapore.ORCID 0000-0002-3423-2155
Daniel Q HuangDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.ORCID 0000-0002-5165-5061
Timothy Wai Ho ShuenDepartment of Medical Oncology, National Cancer Centre Singapore, Singapore.ORCID 0000-0001-9305-7652
Han Chong TohDepartment of Medical Oncology, National Cancer Centre Singapore, Singapore.ORCID 0000-0003-0642-3453
Yock Young DanDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.ORCID 0000-0002-7546-2117
Lars ZenderDepartment of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tübingen, Germany.ORCID 0000-0001-7626-2849
Torsten WuestefeldLaboratory of In Vivo Genetics & Gene Therapy, Genome Institute of Singapore, Singapore.ORCID 0000-0002-0639-6048
Genome Institute of Singapore · SGNational Cancer Centre Singapore · SGNational University of Singapore · SGGerman Cancer Research Center · DENanyang Technological University · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unfortunately, available liver cancer treatments are associated with modest survival advantage. The biggest factor improving survival is early detection, but the current understanding of early transformation events is limited. Therefore, we set up a model to study these early events and investigated the relationship of premalignant, senescent hepatocytes, a regenerative environment, and the influence of secreted factors on liver tumorigenesis. Oncogene-induced senescence (OIS) was triggered in a subset of mouse hepatocytes, which under normal conditions, are eliminated by immunosurveillance. Inducing liver damage and regeneration was sufficient to trigger immunosurveillance escape of OIS hepatocytes, resulting in premalignant to malignant transformation and hepatocellular tumor development. Trefoil factor 3 (TFF3) was found to be overexpressed in OIS hepatocytes and in hepatocellular carcinoma. TFF3 deficiency strongly attenuated malignant transformation by increasing insulin-like growth factor binding protein 5 (IGFBP5) expression, which consequently dampened IGF receptor signaling. Furthermore, analysis of precancerous liver tissue validated TFF3 as an early liver cancer biomarker. Altogether, these findings provide mechanistic insights into early transformation and immunosurveillance escape in liver cancer, revealing TFF3 and IGFBP5 to be important players with opposite roles in tumorigenesis. SIGNIFICANCE: Liver damage induces a compensatory regenerative response that can drive premalignant to malignant transformation of senescent hepatocytes.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsPrecancerous ConditionsAnimalsCell Transformation, NeoplasticHepatocytesMice

Identifiers

PMID36449018
PMCPMC9896023
OpenAlexW4310458728

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.